{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:36:17Z","timestamp":1782318977808,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["IIS 53234545"],"award-info":[{"award-number":["IIS 53234545"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.lungcan.2020.07.022","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T13:13:18Z","timestamp":1595855598000},"page":"48-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients"],"prefix":"10.1016","volume":"148","author":[{"given":"Nir","family":"Peled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Gillis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Froesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei","family":"Orlov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Filippova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Cicin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Bugdayci","family":"Basal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cengiz","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moiseenko","family":"Fedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taner","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semra","family":"Paydas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gautschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisan","family":"Zirtiloglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yesim","family":"Eralp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havva Yesil","family":"Cinkir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Sezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Tural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hande","family":"Turna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Mazieres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Dudnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi","family":"Reguart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Ross","family":"Camidge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry L.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filiz \u00c7ay","family":"\u015eenler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130smail","family":"Beyp\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do\u011fan","family":"Yaz\u0131l\u0131ta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Demirkaz\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Karao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"Okutur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan \u015eenol","family":"Co\u015fkun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali Nahit","family":"\u015eendur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Isikdogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devrim","family":"Cabuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perran Fulden","family":"Yumuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ali","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zg\u00fcr","family":"\u00d6zy\u0131lkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"\u00d6ztop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer Fatih","family":"Olmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Ayd\u0131ner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nezih","family":"Meydan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana Denisa","family":"Grinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila C.","family":"Roisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2020.07.022_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non\u2013small-cell lung cancer","volume":"377.9","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0010","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non\u2013small cell lung cancer in the global phase III ALEX study","volume":"14.7","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0015","series-title":"Final PFS Analysis and Safety Data From the Phase III J-ALEX Study of Alectinib (ALC) vs. Crizotinib (CRZ) in ALK-Inhibitor Na\u00efve ALK-positive Non-Small Cell Lung Cancer (ALK+ NSCLC)","first-page":"9092","author":"Seto","year":"2019"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0020","series-title":"Brigatinib (BRG) in Patients (pts) With Crizotinib (CRZ)-Refractory ALK+ Non-Small Cell Lung Cancer (NSCLC): First Report of Efficacy and Safety From a Pivotal Randomized Phase (ph) 2 Trial (ALTA)","first-page":"9007","author":"Kim","year":"2016"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/clpt.2013.200","article-title":"Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer","volume":"95","author":"Solomon","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0030","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non\u2013small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0035","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.2012.44.5353","article-title":"ALK in lung cancer: past, present, and future","volume":"31","author":"Shaw","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0040","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-16-1123","article-title":"Precision medicine takes on drug resistance","volume":"7","author":"Lin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0045","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0050","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0055","first-page":"37","article-title":"The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer","volume":"1795","author":"Acquaviva","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0060","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1634\/theoncologist.2013-0095","article-title":"Novel targets in non-small cell lung cancer: ROS1 and RET fusions","volume":"18","author":"Gainor","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0065","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0070","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.jtho.2017.08.002","article-title":"Recent advances in targeting ROS1 in lung Cancer","volume":"12","author":"Lin","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2020.07.022_bib0075","doi-asserted-by":"crossref","first-page":"S459","DOI":"10.1016\/j.jtho.2019.08.950","article-title":"P1. 04-47 tumor mutation burden through hybrid capture\u2013circulating tumor DNA may predict response to immunotherapy in NSCLC","volume":"14","author":"Grinberg","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2020.07.022_bib0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jtho.2016.10.021","article-title":"Clinical impact of hybrid capture\u2013based next-generation sequencing on changes in treatment decisions in lung cancer","volume":"12","author":"Rozenblum","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"June (6)","key":"10.1016\/j.lungcan.2020.07.022_bib0085","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2015-0497","article-title":"Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization","volume":"21","author":"Ali","year":"2016","journal-title":"Oncologist"},{"issue":"March (3)","key":"10.1016\/j.lungcan.2020.07.022_bib0090","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1634\/theoncologist.2014-0389","article-title":"Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer","volume":"20","author":"Pekar-Zlotin","year":"2015","journal-title":"Oncologist"},{"issue":"September (9)","key":"10.1016\/j.lungcan.2020.07.022_bib0095","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/JTO.0b013e3182614ab5","article-title":"Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non\u2013small-cell lung cancer","volume":"7","author":"Peled","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"October (10)","key":"10.1016\/j.lungcan.2020.07.022_bib0100","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11864-019-0675-9","article-title":"Diagnosis and treatment of ALK aberrations in metastatic NSCLC","volume":"20","author":"Friedlaender","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0105","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1007\/s40265-019-01164-3","article-title":"Targeting ROS1 rearrangements in non-small cell lung cancer: crizotinib and newer generation tyrosine kinase inhibitors","volume":"79.12","author":"Morris","year":"2019","journal-title":"Drugs"},{"issue":"January (1)","key":"10.1016\/j.lungcan.2020.07.022_bib0110","first-page":"7","article-title":"Lorlatinib in ROS1-positive NSCLC","volume":"17","author":"Killock","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2020.07.022_bib0115","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1097\/JTO.0b013e3182570919","article-title":"Pre-clinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer","volume":"7","author":"Yasuda","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0120","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non\u2013small-cell lung cancer","volume":"371.21","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.lungcan.2020.07.022_bib0125","first-page":"S322","article-title":"OA02.03 clinical activity of Lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: phase 2 study cohort EXP-6 ou, S. et al","volume":"13","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"October (suppl_8)","key":"10.1016\/j.lungcan.2020.07.022_bib0130","article-title":"1380PD, Efficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations","volume":"29","author":"Solomon","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0135","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small cell lung cancer with ALK or ROS1 rearrangement: an international, multicenter, open-label, single-arm, first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0140","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0145","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"issue":"June (16)","key":"10.1016\/j.lungcan.2020.07.022_bib0150","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of Lorlatinib in advanced anaplastic lymphoma kinase-positive non\u2013small-cell lung Cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0160","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(15)70057-4","article-title":"Response assessment criteria for brain metastases: proposal from the RANO group","volume":"16.6","author":"Lin","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45.2","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0170","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small cell lung cancer with ALK or ROS1 rearrangement: an international, multicenter, open-label, single-arm, first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.07.022_bib0175","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(19)30655-2","article-title":"Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1\u20132 trial","author":"Shaw","year":"2019","journal-title":"Lancet Oncol."},{"issue":"October","key":"10.1016\/j.lungcan.2020.07.022_bib0180","doi-asserted-by":"crossref","first-page":"v608","DOI":"10.1093\/annonc\/mdz260.009","article-title":"Intracranial and extracranial efficacy of lorlatinib in the post second-generation ALK tyrosine kinase inhibitor (TKI) setting","volume":"30","author":"Camidge","year":"2019","journal-title":"Ann. Oncol."},{"issue":"January (1)","key":"10.1016\/j.lungcan.2020.07.022_bib0185","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/1759-7714.13259","article-title":"Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non\u2010EML4\u2010ALK rearrangements detected from cerebrospinal fluid: a case report","volume":"11","author":"Li","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2020.07.022_bib0190","series-title":"Final PFS Analysis and Safety Data From the Phase III J-ALEX Study of Alectinib (ALC) vs. Crizotinib (CRZ) in ALK-Inhibitor Na\u00efve ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC)","first-page":"9092","author":"Seto","year":"2019"},{"issue":"20","key":"10.1016\/j.lungcan.2020.07.022_bib0195","first-page":"39796","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"S0923-7534","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2020.07.022_bib0200","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220305468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:43:11Z","timestamp":1759236191000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220305468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":40,"alternative-id":["S0169500220305468"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.022","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}